TITLE

NeoPharm's cancer compound could be a potential Taxol rival

PUB. DATE
December 2004
SOURCE
PharmaWatch: Cancer;December2004, Vol. 3 Issue 12, p5
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
Reports on the results of NeoPharm Inc.'s phase I clinical trials which found the safety and tolerability of the NeoLipid compound, LEP-ETU, in patients with advanced female cancers. Consideration of LEP-ETU as NeoPharm's liposomal formulation of paclitaxel, a chemotherapeutic drug in wide use for the treatment of several forms of advanced cancer; Tolerance of paclitaxel's side effects by the majority of patients; Assertion of Mayer Fishman, one of the lead investigators, about the need of further studies to assess the safety and efficacy of LEP-ETU.
ACCESSION #
17641978

 

Related Articles

  • Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Huebner, G.; Link, H.; Kohne, C. H.; Stahl, M.; Kretzschmar, A.; Steinbach, S.; Folprecht, G.; Bernhard, H.; Al-Batran, S. E.; Schoffski, P.; Burkart, C.; Kullmann, F.; Otremba, B.; Menges, M.; Hoffmann, M.; Kaiser, U.; Aldaoud, A.; Jahn, A. // British Journal of Cancer;1/13/2009, Vol. 100 Issue 1, p44 

    Platinum/taxane combinations are widely used in patients with carcinoma of unknown primary (CUP), yielding response rates of 30% and median overall survival of 9–11 months in selected patients. Yet these combinations have not been subject to a randomised trial to overcome selection bias,...

  • Bevacizumab plus paclitaxel can slow breast cancer progression but does not improve overall survival.  // Formulary;Mar2008, Vol. 43 Issue 3, p115 

    The article reports on the findings of the clinical trial regarding the efficacy of the drug bevacizumab when administered with paclitaxel in breast cancer patients. It states that the addition of bevacizumab to treatment with paclitaxel does not extend the overall survival of cancer patients....

  • NeoPharm colorectal cancer drug misses target.  // PharmaWatch: Cancer;May2007, Vol. 6 Issue 5, p16 

    The article reports on the announcement of biopharmaceutical company NeoPharm Inc. on the failure of its phase II trial in second-line metastatic colorectal cancer patients with its product LESN38 to produce the desired results. While the interim analysis of data following the completion of...

  • EOPHARM BEGINS TRIAL OF IL13-PE38 FOR MALIGNANT GLIOMA.  // Worldwide Biotech;Oct2002, Vol. 14 Issue 10, p4 

    Highlights progress on the clinical development program of NeoPharm Inc. for IL13-PE38, a novel tumor-targeted agent.

  • NeoPharm regains rights to cancer drugs.  // PharmaWatch: Biotechnology;November 2004, Vol. 3 Issue 11, p15 

    Reports that NeoPharm will seek U.S. approval for a unique formulation of paclitaxel after the biotechnology firm regained commercialization rights to investigational cancer drugs previously licensed to Pfizer. Efforts of NeoPharm to terminate its license agreement with Pfizer since 2002; Plan...

  • Disease-free survival was greater with letrozole than tamoxifen in postmenopausal women with early breast cancer: COMMENTARY. Prowell, Tatiana M.; Stearns, Vered // ACP Journal Club;Jul/Aug2006, Vol. 145 Issue 1, p11 

    The article presents the author's views on a study that postmenopausal women with early breast cancer who received aromatase inhibitors with tamoxifen, had greater chances of disease-free survival than those women who received only tamoxifen. Most of the clinical trials have demonstrated trends...

  • Human Genome Sciences' genomics- derived anticancer drug enters phase II trials.  // PharmaWatch: Cancer;December2004, Vol. 3 Issue 12, p11 

    Reports that Human Genome Sciences Inc. has begun two phase II clinical trials to evaluate the efficacy of agonistic human monoclonal antibody to TRAIL receptor-1 (HGS-ETR1) in advanced non-Hodgkin's lymphoma and colorectal cancer patients. Clinical trial objectives; Comments of Craig A. Rosen,...

  • BioCyst begins phase I trial of oral T-cell cancer compound.  // PharmaWatch: Cancer;December2004, Vol. 3 Issue 12, p12 

    Reports that BioCryst Pharmaceuticals Inc. has initiated its phase I trial of anticancer compound, oral forodesine hydrochloride, in refractory patients with cutaneous T-cell lymphoma (CTCL). Objective of the trial to study the pharmacokinetic effects of the drug at 40, 80, 160mg/m2 levels;...

  • COMPANY SPOTLIGHT - Bayer AG.  // PharmaWatch: Cancer;December2004, Vol. 3 Issue 12, p21 

    Reports on the results of the recent phase II trial of Bayer AG's anticancer drug, BAY 43-9006. Percentage of kidney cancer patients who showed either tumor shrinkage or disease stabilization after administration of BAY 43-9006; Adverse events experienced by cancer patients; Description on how...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics